AN OVERVIEW OF PROGNOSTIC MARKERS IN BREAST CANCER

Area of Science:

• Oncology
• Pathology
• Molecular Biology

Background:

• Axillary lymph node metastasis has historically been the primary prognostic factor in breast cancer.
• Traditional factors (age, tumor size, grade) and lymph node status alone often fail to accurately predict prognosis.
• Newer biological and molecular markers show promise in identifying high-risk breast cancer patients.

Purpose of the Study:

• To review key biological and molecular parameters for breast cancer prognosis.
• To identify cost-effective markers that accurately predict patient outcomes.
• To guide oncologists in selecting appropriate prognostic indicators.

Main Methods:

• Literature review of established and emerging prognostic markers in breast cancer.
• Analysis of biological and molecular parameters including Estrogen Receptor (ER), Progesterone Receptor (PR), S phase fraction, DNA ploidy, MIB-1 antibody, p53, C-erb-2, nm23, Cathepsin, and Topoisomerase II alpha.
• Evaluation of the predictive capabilities and cost-effectiveness of these markers.

Main Results:

• Selected biological markers offer enhanced prognostic accuracy compared to traditional factors alone.
• Certain markers can effectively identify 'high risk' patient groups.
• A comprehensive analysis of all markers may not be essential or cost-effective for all cases.

Conclusions:

• Biological and molecular markers are crucial for accurate breast cancer prognosis.
• A judicious selection of key markers can improve risk stratification and treatment decisions.
• Further research into cost-effective prognostic panels is warranted.